Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis.

Breast Cancer (Dove Med Press) · 2018 · PMC6257362 · PMID 30538542

Europe PMC DOI

hedged sentence

0.7460

closest p · 14.9× alpha

0.7460

boldest claim

The sentences

did not reach statistical significanceP =0.746not close (p > 0.1)

73 Our Bcl2-negative patients in the TNBC group had a poorer outcome (78.79 months; 95% CI: 63.64–93.95) than those in the Bcl2-positive group (86.43 months; 95% CI: 72.91–99.95), although the difference did not reach statistical significance (HR =1.19; 95% CI: 0.42–3.39; P =0.746).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.